584 related articles for article (PubMed ID: 33407585)
1. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
[TBL] [Abstract][Full Text] [Related]
2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
4. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.
Wu R; Gao Y; Zhao X; Guo S; Zhou H; Zhang Y; Hou Y; Mei L; Zhi H; Wang P; Li X; Ning S; Zhang Y
Comput Biol Med; 2023 Dec; 167():107593. PubMed ID: 37883849
[TBL] [Abstract][Full Text] [Related]
5. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Hong T; Su W; Pan Y; Tian C; Lei G
Front Immunol; 2022; 13():951459. PubMed ID: 36189258
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.
Sun L; Liu Z; Wu Z; Ning K; Hu J; Chen Z; Wu Z; Yin X
Front Immunol; 2023; 14():1113455. PubMed ID: 37051238
[TBL] [Abstract][Full Text] [Related]
7. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.
Guo Y; Yang J; Ren K; Tian X; Gao H; Tian X; Zhang X; Kan Q
Front Immunol; 2022; 13():861525. PubMed ID: 35355983
[TBL] [Abstract][Full Text] [Related]
8. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
9. Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy.
Yang J; Zeng L; Chen R; Zheng S; Zhou Y; Chen R
Front Immunol; 2023; 14():1076587. PubMed ID: 37006288
[TBL] [Abstract][Full Text] [Related]
10. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.
Qu J; Sun F; Hou Y; Qi H; Sun X; Xing L
BMC Cancer; 2023 Jun; 23(1):549. PubMed ID: 37322434
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma.
Guo C; Tang Y; Li Q; Yang Z; Guo Y; Chen C; Zhang Y
Comput Biol Med; 2023 May; 158():106872. PubMed ID: 37030269
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma.
Liu L; Liu Z; Gao J; Liu X; Weng S; Guo C; Hu B; Wang Z; Zhang J; Shi J; Guo W; Zhang S
Front Immunol; 2022; 13():964190. PubMed ID: 35967384
[TBL] [Abstract][Full Text] [Related]
14. Molecular phenotypic linkage between N
Zhang F; Bi J; Liao J; Zhong W; Yu M; Lu X; Che J; Chen Z; Xu H; Hu S; Liu Y; Guo S
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6901-6916. PubMed ID: 36826593
[TBL] [Abstract][Full Text] [Related]
15. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma.
Gao B; Wang Y; Lu S
Sci Rep; 2023 Jan; 13(1):1137. PubMed ID: 36670201
[TBL] [Abstract][Full Text] [Related]
16. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.
Khemlina G; Ikeda S; Kurzrock R
Mol Cancer; 2017 Aug; 16(1):149. PubMed ID: 28854942
[TBL] [Abstract][Full Text] [Related]
17. Immune Landscape Refines the Classification of Colorectal Cancer With Heterogeneous Prognosis, Tumor Microenvironment and Distinct Sensitivity to Frontline Therapies.
Liu Z; Guo Y; Yang X; Chen C; Fan D; Wu X; Si C; Xu Y; Shao B; Chen Z; Dang Q; Cui W; Han X; Ji Z; Sun Z
Front Cell Dev Biol; 2021; 9():784199. PubMed ID: 35083217
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in hepatocellular carcinoma.
Buonaguro L; Mauriello A; Cavalluzzo B; Petrizzo A; Tagliamonte M
Ann Hepatol; 2019; 18(2):291-297. PubMed ID: 31047849
[TBL] [Abstract][Full Text] [Related]
19. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
Yuan J; Liu Z; Wu Z; Yang J; Yang J
Int Immunopharmacol; 2022 Dec; 113(Pt A):109411. PubMed ID: 36461603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
